Synergy (SGYP) Initiating Second Plecanatide Phase 3 is 'Sign of Confidence' - Aegis
Get Alerts SGYP Hot Sheet
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 14 | New: 22
Join SI Premium – FREE
Aegis Capital affirms Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP) at Buy with a price target of $28 following news that the company initiated its second phase 3 for plecanatide.
Analyst Ram Selvaraju commented, We note that the initiation of this study should be seen as a significant indicator of the firm's confidence in the efficacy and safety of plecanatide in CIC, and would remind investors that the upcoming release of data from the Phase 2b trial of plecanatide in irritable bowel syndrome of the constipationpredominant subtype (IBS-C) is slated to occur imminently.
For an analyst ratings summary and ratings history on Synergy Pharmaceuticals click here. For more ratings news on Synergy Pharmaceuticals click here.
Shares of Synergy Pharmaceuticals closed at $4.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
- Darden Restaurants (DRI) PT Raised to $190 at Stifel
- CFRA Upgrades Vodafone (VOD) to Hold
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!